+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Hospital Acquired Infection"

Antimicrobial Resistance Diagnostics Market Report 2026 - Product Thumbnail Image

Antimicrobial Resistance Diagnostics Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Clostridium Difficile Infections - Pipeline Insight, 2026 - Product Thumbnail Image

Clostridium Difficile Infections - Pipeline Insight, 2026

  • Clinical Trials
  • April 2026
  • 80 Pages
  • Global
From
From
From
From
From
Surgical Site Infection (SSI) Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Surgical Site Infection (SSI) Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
From
From
Infection Control Market - Forecasts from 2025 to 2030 - Product Thumbnail Image

Infection Control Market - Forecasts from 2025 to 2030

  • Report
  • August 2025
  • 145 Pages
  • Global
From
From
From
From
From
From
From
From
From
Loading Indicator

The Hospital Acquired Infection (HAI) market is a subset of the Infectious Diseases Drugs market. HAIs are infections that occur in a hospital setting, and can be caused by a variety of bacteria, viruses, and fungi. These infections can be difficult to treat, as they are often resistant to antibiotics. As such, HAI drugs are designed to target specific pathogens, and are often used in combination with other treatments. The HAI market is driven by the increasing prevalence of antibiotic-resistant infections, as well as the need for more effective treatments. Additionally, the rising number of hospitalizations due to chronic illnesses has also contributed to the growth of the market. Some of the major players in the HAI market include Merck & Co., Pfizer, GlaxoSmithKline, Sanofi, and Johnson & Johnson. These companies are actively developing new drugs and treatments to address the growing prevalence of HAIs. Show Less Read more